Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Citi Starts Forte Biosciences Inc. (FBRX) at Buy
March 26, 2021 5:20 AM EDTCiti analyst Mohit Bansal initiates coverage on Forte Biosciences Inc. (NASDAQ: FBRX) with a Buy rating and a price target of $75.00.
The analyst comments "We are initiating coverage of Forte (FBRX) with a Buy (High-Risk) as we think FB-401, the companys... More
Forte Biosciences (FBRX) Misses Q4 EPS by 17c
March 24, 2021 8:03 AM EDTForte Biosciences (NASDAQ: FBRX) reported Q4 EPS of ($0.74), $0.17 worse than the analyst estimate of ($0.57).
Forte made significant progress in the fourth quarter of 2020. In September, we initiated a randomized trial of FB-401 in atopic dermatitis patients, including adults and children 2... More
